GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ADMA Biologics Inc (NAS:ADMA) » Definitions » Cyclically Adjusted FCF per Share

ADMA (ADMA Biologics) Cyclically Adjusted FCF per Share : $-1.21 (As of Mar. 2025)


View and export this data going back to 2013. Start your Free Trial

What is ADMA Biologics Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

ADMA Biologics's adjusted free cash flow per share for the three months ended in Mar. 2025 was $-0.100. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-1.21 for the trailing ten years ended in Mar. 2025.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 10.80% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 2.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of ADMA Biologics was 10.80% per year. The lowest was -6.10% per year. And the median was 1.30% per year.

As of today (2025-07-05), ADMA Biologics's current stock price is $18.28. ADMA Biologics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was $-1.21. ADMA Biologics's Cyclically Adjusted Price-to-FCF of today is .


ADMA Biologics Cyclically Adjusted FCF per Share Historical Data

The historical data trend for ADMA Biologics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ADMA Biologics Cyclically Adjusted FCF per Share Chart

ADMA Biologics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.55 -1.75 -1.67 -1.49 -1.24

ADMA Biologics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.44 -1.37 -1.31 -1.24 -1.21

Competitive Comparison of ADMA Biologics's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, ADMA Biologics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ADMA Biologics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ADMA Biologics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where ADMA Biologics's Cyclically Adjusted Price-to-FCF falls into.


;
;

ADMA Biologics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ADMA Biologics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.1/134.9266*134.9266
=-0.100

Current CPI (Mar. 2025) = 134.9266.

ADMA Biologics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -0.416 100.684 -0.557
201509 -0.250 100.392 -0.336
201512 -0.393 99.792 -0.531
201603 -0.484 100.470 -0.650
201606 -0.400 101.688 -0.531
201609 -0.364 101.861 -0.482
201612 -0.281 101.863 -0.372
201703 -0.419 102.862 -0.550
201706 -0.540 103.349 -0.705
201709 -0.400 104.136 -0.518
201712 -0.339 104.011 -0.440
201803 -0.375 105.290 -0.481
201806 -0.361 106.317 -0.458
201809 -0.276 106.507 -0.350
201812 -0.423 105.998 -0.538
201903 -0.311 107.251 -0.391
201906 -0.359 108.070 -0.448
201909 -0.432 108.329 -0.538
201912 -0.358 108.420 -0.446
202003 -0.362 108.902 -0.449
202006 -0.295 108.767 -0.366
202009 -0.305 109.815 -0.375
202012 -0.370 109.897 -0.454
202103 -0.310 111.754 -0.374
202106 -0.288 114.631 -0.339
202109 -0.121 115.734 -0.141
202112 -0.205 117.630 -0.235
202203 -0.147 121.301 -0.164
202206 -0.085 125.017 -0.092
202209 -0.085 125.227 -0.092
202212 -0.055 125.222 -0.059
202303 -0.075 127.348 -0.079
202306 -0.031 128.729 -0.032
202309 0.048 129.860 0.050
202312 0.072 129.419 0.075
202403 -0.019 131.776 -0.019
202406 0.179 132.554 0.182
202409 0.098 133.029 0.099
202412 0.191 133.157 0.194
202503 -0.100 134.927 -0.100

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


ADMA Biologics  (NAS:ADMA) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


ADMA Biologics Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of ADMA Biologics's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


ADMA Biologics Business Description

Industry
Traded in Other Exchanges
N/A
Address
465 State Route 17, Ramsey, NJ, USA, 07446
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
Executives
Lawrence P. Guiheen director 65 COMMERCE WAY, HACKENSACK NJ 07601
Adam S Grossman director, officer: President and CEO 65 COMMERCE WAY, HACKENSACK NJ 07601
Jerrold B Grossman director 65 COMMERCE WAY, HACKENSACK NJ 07601
Young Kwon director C/O MOMENTA PHARMACEUTICALS INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Steve Elms director 888 SEVENTH AVE, 29TH FL, NEW YORK NY 10106
Alison Cecily Finger director C/O BLUEBIRD BIO, INC., 60 BINNEY STREET, CAMBRIDGE MA 02142
Bryant Fong director 2170 VALLEJO STREET #101, SAN FRANCISCO CA 94123
Brian Lenz officer: EVP, CFO 65 COMMERCE WAY, HACKENSACK NJ 07601
Martha J Demski director 7770 REGENTS ROAD SUITE 113-505, SAN DIEGO CA 92122
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
James Mond officer: CSO/CMO 65 COMMERCE WAY, HACKENSACK NJ 07601
Biotest Divestiture Trust 10 percent owner C/O ERIC ROSENBACH, TRUSTEE, 402 NORFOLK STREET, CAMBRIDGE MA 02139
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Eric I Richman director C/O REV CAPITAL II, LLC, 9740 SORREL AVE, POTOMAC MD 20854